[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349914-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349914-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prothrombotic-tendency-in-the-shadow-of-cancer-hypercoagulability-impaired-clot-contraction-and-fibrinolysis-in-colorectal-cancer-and-gastric-cancer-patients-undergoing-chemotherapy","Prothrombotic Tendency in the Shadow of Cancer - Hypercoagulability, Impaired Clot Contraction and Fibrinolysis in Colorectal Cancer and Gastric Cancer Patients Undergoing Chemotherapy","","Cancer is frequently accompanied by thrombotic complications, yet routine coagulation tests may not reliably detect cancer-associated hypercoagulability. Blood from 34 patients with colorectal or gastric cancers, sampled before, during, and after three months of chemotherapy, and from 21 healthy controls was used to generate a coagulation–fibrinolysis profile via thromboelastometry and to assess clot contraction kinetics (CCR). Patients showed hypercoagulable profiles with shortened clotting time, stronger clots, reduced CCR, and impaired fibrinolysis, more pronounced in colorectal cancer. Chemotherapy prolonged fibrinolysis and platinum-based drugs supported this effect in vitro. Findings indicate significant CCR inhibition in cancer and suggest that combining thromboelastometry with CCR could improve stratification of thrombotic risk. The work highlights hemostatic imbalance that may extend clot persistence by reducing fibrinolysis while lowering clot stability through impaired CCR, underscoring the need for careful monitoring of thrombotic versus bleeding tendencies in cancer patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prothrombotic-tendency-in-the-shadow-of-cancer-hypercoagulability-impaired-clot-contraction-and-fibrinolysis-in-colorectal-cancer-and-gastric-cancer-patients-undergoing-chemotherapy/349914/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prothrombotic-tendency-in-the-shadow-of-cancer-hypercoagulability-impaired-clot-contraction-and-fibrinolysis-in-colorectal-cancer-and-gastric-cancer-patients-undergoing-chemotherapy/349914.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do conventional coagulation tests often fail to detect cancer-associated hypercoagulability?","Question",{"text":63,"@type":64},"Routine coagulation tests may not adequately capture the specific hemostatic disturbances linked to cancer-associated hypercoagulability. The study addresses this by using thromboelastometry and clot contraction kinetics (CCR) to generate a more informative coagulation–fibrinolysis profile.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What coagulation and fibrinolysis differences were observed between cancer patients and healthy controls?",{"text":68,"@type":64},"Compared with healthy controls, cancer patients demonstrated a hypercoagulable profile: shortened clotting time, enhanced clot strength, reduced CCR, and impaired fibrinolysis. The effects were more pronounced in colorectal cancer patients.",{"name":70,"@type":61,"acceptedAnswer":71},"How did chemotherapy affect fibrinolysis and what was seen with platinum-based drugs in vitro?",{"text":72,"@type":64},"Chemotherapy meaningfully prolonged fibrinolysis. This was further supported in vitro using platinum-based drugs, showing an additional chemotherapy-related effect on fibrinolytic activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349914,1790195062,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Article  \nProthrombotic Tendency in the Shadow of Cancer: Hypercoagulability, Impaired Clot Contraction and Fibrinolysis in Colorectal Cancer and Gastric Cancer Patients Undergoing Chemotherapy  \nKarolina Aleksandrowicz 1,2, Tomasz Rusak 3, *, Elbieta Bołtromiuk 3, Tomasz Misztal 3, Barbara Polity ´nska-Lewko 4, Anna M. Wojtukiewicz 4, Joanna Kruszewska 5, Marta My´sliwiec 5 and Marek Z. Wojtukiewicz 1, *  \nAcademic Editor: Cristiano Fava  \nReceived: 14 January 2026  \nRevised: 13 February 2026  \nAccepted: 19 February 2026  \nPublished: 21 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, Waszyngtona 15 B, 15-269 Bialystok, Poland; [karolina.aleksandrowicz@sd.umb.edu.pl](karolina.aleksandrowicz@sd.umb.edu.pl)  \n[2](2 Bialystok Oncology Center)[ Bialystok Oncology Center](2 Bialystok Oncology Center), [Ogrodowa 12](Ogrodowa 12), [15-022 Bialystok](15-022 Bialystok), [Poland](Poland)  \n3 Department of Physical Chemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222 Bialystok, Poland; [elzbieta.boltromiuk@umb.edu.pl](elzbieta.boltromiuk@umb.edu.pl) (E.B.); [tomasz.misztal@umb.edu.pl](tomasz.misztal@umb.edu.pl) (T.M.)  \n4 Department of Psychology and Philosophy, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Poland; [barbara.politynska-lewko@umb.edu.pl](barbara.politynska-lewko@umb.edu.pl) (B.P.-L.); [aniawojtukiewicz@gmail.com](aniawojtukiewicz@gmail.com) (A.M.W.)  \n5 Department of Oncology, Medical University of Bialystok, Ogrodowa 12, 15-269 Bialystok, Poland; [joanna.kruszewska@umb.edu.pl](joanna.kruszewska@umb.edu.pl) (J.K.); [marta.mysliwiec@umb.edu.pl](marta.mysliwiec@umb.edu.pl) (M.M.)  \n* Correspondence: [tomasz.rusak@umb.edu.pl](tomasz.rusak@umb.edu.pl) (T.R.); [marek.wojtukiewicz@umb.edu.pl](marek.wojtukiewicz@umb.edu.pl) (M.Z.W.)  \nAbstract  \nCancer is frequently accompanied by thrombotic complications, but conventional coagulation tests often fail to adequately detect cancer-associated hypercoagulability. In this study, blood from 34 patients with colorectal or gastric cancers (before, during and after 3 months of chemotherapy) and 21 healthy controls was analyzed to obtain a coagulation– fibrinolysis profile (by thromboelastometry) and determine the kinetics of clot contraction (CCR). Patients demonstrated hypercoagulable profiles characterized by shortened clotting time, enhanced clot strength, reduced CCR, and impaired fibrinolysis compared to healthy controls, which was more pronounced in colorectal cancer patients. Parameters related to increased clot formation, impaired CC and delayed fibrinolysis correlated with disease stage. Chemotherapy meaningfully prolonged fibrinolysis, which was further evident in vitro with platinum-based drugs. Our findings reveal, for the first time, a significant inhibition of CCR in cancer patients. Integrating thromboelastometry with CCR measurements may improve stratification of cancer-associated thrombotic risk, which appears to arise from the hemostatic disturbances identified in our study. These may extend the duration of clot presence due to reduced fibrinolysis, while decreasing clot stability through diminished CCR. Therefore, careful monitoring of the precarious balance between thrombotic and bleeding tendencies may hold important implications for the fate of cancer patients.  \nKeywords: hypercoagulability; clot contraction; fibrinolysis; cancer; chemotherapy  \n1. Introduction  \nCancer is frequently associated with profound disturbances of hemostasis, leading to thrombotic, hemorrhagic or thrombo-hemorrhagic complications. Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, represents  \nthe second leading cause of death among patients with c","cbCaim3yYhdp4Ofb","https://ap.wps.com/l/cbCaim3yYhdp4Ofb","pdf",1233905,14,"English","# Introduction\n## Venous thromboembolism risk and prognosis in cancer\n## Hemorrhagic complications and hemostatic imbalance\n## Clot contraction and fibrinolysis in restoring blood flow","[{\"question\":\"Why do conventional coagulation tests often fail to detect cancer-associated hypercoagulability?\",\"answer\":\"Routine coagulation tests may not adequately capture the specific hemostatic disturbances linked to cancer-associated hypercoagulability. The study addresses this by using thromboelastometry and clot contraction kinetics (CCR) to generate a more informative coagulation–fibrinolysis profile.\"},{\"question\":\"What coagulation and fibrinolysis differences were observed between cancer patients and healthy controls?\",\"answer\":\"Compared with healthy controls, cancer patients demonstrated a hypercoagulable profile: shortened clotting time, enhanced clot strength, reduced CCR, and impaired fibrinolysis. The effects were more pronounced in colorectal cancer patients.\"},{\"question\":\"How did chemotherapy affect fibrinolysis and what was seen with platinum-based drugs in vitro?\",\"answer\":\"Chemotherapy meaningfully prolonged fibrinolysis. This was further supported in vitro using platinum-based drugs, showing an additional chemotherapy-related effect on fibrinolytic activity.\"}]","Prothrombotic Tendency in the Shadow of Cancer - Hypercoagulability, Impaired Clot Contraction and Fibrinolysis in Colorectal Cancer and Gastric Cancer Patients Undergoing Chemotherapy | PDF",1790086241,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/948764ca9c60a10b568df544f6bbce66.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c660f29031c1d42cdf908851173ffc8.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53138ce172797ff281a15175b98ff3ce.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fef620eab5107e1ee4fe56634aeaa84.webp",980,1385]